Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Dentsply International / Equity Bottom-Up

<ul><li>The second quarter of 2026 for Dentsply Sirona reflected a continued transitional phase as the company progresses through its 24-month Return-to-Growth Action Plan.</li><li>Reported revenues declined by 4.1% to $898 million, or 6.3% on a constant currency basis, though after adjusting for the divestiture of Byte and planned dealer inventory reductions, the decline was somewhat mitigated to 3.6%.</li><li>Earnings per share remained stable at $0.52, benefiting from $44 million in tariff refunds which contributed approximately $0.17 per share.</li></ul>

The second quarter of 2026 for Dentsply Sirona reflected a continued transitional phase as the company progresses through its 24-month Return-to-Growth Action Plan.Reported revenues declined by 4.1% to $898 million, or 6.3% on a constant currency basis, though after adjusting for the divestiture of Byte and planned dealer inventory reductions, the decline was somewhat mitigated to 3.6%.Earnings per share remained stable at $0.52, benefiting from $44 million in tariff refunds which contributed approximately $0.17 per share.

Dentsply Sirona’s $99 Million Cash Flow Surge: Is The Turnaround Taking Hold?

Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Index Rebalance

<ul>
<li>The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.</li>
<li>The index is reviewed quarterly. The next review will be in June 2024 and the evaluation date for the rankings for the constituent selection process is 6th June 2024.</li>
<li>In this insight, we take a look at the Potential ADDs and Potential DELs for the June 2024 index rebal event and the intra-review ADDs/DELETEs.</li>
</ul>


The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.
The index is reviewed quarterly. The next review will be in June 2024 and the evaluation date for the rankings for the constituent selection process is 6th June 2024.
In this insight, we take a look at the Potential ADDs and Potential DELs for the June 2024 index rebal event and the intra-review ADDs/DELETEs.


Quiddity Leaderboard S&P 500 Jun 24 Rebal: Many Intra-Review Changes Possible Due to M&A, Spin-Offs

<ul>
<li>The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.</li>
<li>The index is reviewed quarterly. The next review will be in June 2024 and the evaluation date for the rankings for the constituent selection process is 6th June 2024.</li>
<li>In this insight, we take a look at the Potential ADDs and Potential DELs for the June 2024 index rebal event and the intra-review ADDs/DELs.</li>
</ul>


The S&amp;P 500 index tracks the 500 largest names listed in the US and it is one of the most highly-tracked indices in the world.
The index is reviewed quarterly. The next review will be in June 2024 and the evaluation date for the rankings for the constituent selection process is 6th June 2024.
In this insight, we take a look at the Potential ADDs and Potential DELs for the June 2024 index rebal event and the intra-review ADDs/DELs.


Quiddity Leaderboard S&P 500 June 2024 - Minimal Changes Expected but Intrareview Changes Possible

<ul><li>DENTSPLY SIRONA reported first-quarter 2026 results reflecting the early phase of its Return-to-Growth action plan, emphasizing operational restructuring, increased focus on core growth areas, and strategic investments in innovation and customer engagement.</li><li>Total revenue reached $880 million, marking a nominal 0.1% increase as reported but registering a 6.7% decline on a constant currency basis mainly impacted by a strong comparative period in Q1 2025 and the absence of certain treatment center sales.</li><li>Excluding one-time effects, constant currency sales declined 4.5%.</li></ul>

DENTSPLY SIRONA reported first-quarter 2026 results reflecting the early phase of its Return-to-Growth action plan, emphasizing operational restructuring, increased focus on core growth areas, and strategic investments in innovation and customer engagement.Total revenue reached $880 million, marking a nominal 0.1% increase as reported but registering a 6.7% decline on a constant currency basis mainly impacted by a strong comparative period in Q1 2025 and the absence of certain treatment center sales.Excluding one-time effects, constant currency sales declined 4.5%.

Dentsply Sirona's 2026 Reset: Lower Margins, Better Cash Flow & A Growth Plan!

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Dentsply Sirona is navigating a challenging period marked by declining revenues, significant net losses, and substantial impairment charges, primarily linked to its Orthodontic and Implant Solutions segment.</li>
  <li>In response, the company has initiated a significant restructuring plan aiming for approximately $120 million in annualized cost savings, which it intends to reinvest into 'Return-to-Growth' initiatives focused on innovation and commercial execution.</li>
  <li>Management has suspended the quarterly dividend to reallocate capital towards debt reduction and share repurchases, signaling a strategic pivot to stabilize the balance sheet and improve operational efficiency amidst competitive pressures and internal challenges.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Dentsply Sirona is navigating a challenging period marked by declining revenues, significant net losses, and substantial impairment charges, primarily linked to its Orthodontic and Implant Solutions segment.
  In response, the company has initiated a significant restructuring plan aiming for approximately $120 million in annualized cost savings, which it intends to reinvest into 'Return-to-Growth' initiatives focused on innovation and commercial execution.
  Management has suspended the quarterly dividend to reallocate capital towards debt reduction and share repurchases, signaling a strategic pivot to stabilize the balance sheet and improve operational efficiency amidst competitive pressures and internal challenges.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Dentsply International (XRAY US) - Apr 2026

United States

DENTSPLY International Inc. manufactures and distributes dental supplies on a worldwide basis.  The Company's products include dental prosthetics, endodontic instruments, dental sealants, ultrasonic scalers, dental x-ray equipment, and intraoral cameras.  DENTSPLY also provides impression materials, orthodontic appliances, and dental operatory software systems, and other dental products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dentsply International (XRAY US)

Dentsply Sirona’s $99 Million Cash Flow Surge: Is The Turnaround Taking Hold?

The second quarter of 2026 for Dentsply Sirona reflected a continued transitional phase as the company progresses through its 24-month...

Baptista Research

Quiddity Leaderboard S&P 500 Jun 24 Rebal: Many Intra-Review Changes Possible Due to M&A, Spin-Offs

The SP500 will to see up to 4 intra-review changes before the June 2024 rebal. 3 near certain. The interesting ones? Two SP600 deletions due to...

Travis Lundy

Quiddity Leaderboard S&P 500 June 2024 - Minimal Changes Expected but Intrareview Changes Possible

For the moment, there are 1-2 changes expected in Q2 for the S&P500. They could both be intra-review changes but timing is likely to be late. So...

Travis Lundy

Dentsply Sirona's 2026 Reset: Lower Margins, Better Cash Flow & A Growth Plan!

DENTSPLY SIRONA reported first-quarter 2026 results reflecting the early phase of its Return-to-Growth action plan, emphasizing operational...

Baptista Research

Primer: Dentsply International (XRAY US) - Apr 2026

Dentsply Sirona is navigating a challenging period marked by declining revenues, significant net losses, and substantial impairment charges,...

αSK Primers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)